Endologix (ELGX) Stock Price, News & Analysis

Company Overview

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

Key Stats

• Today's Range: $0.07 to $0.08
• 50-Day Range: $0.02 to $0.22
• 52-Week Range: $0.22 to $7.10
• Volume: 85,372 shs
• Average Volume: 1.28 million shs
• Market Capitalization: $1.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ELGX Stock Analysis - Frequently Asked Questions

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) announced its quarterly earnings data on Monday, May, 11th. The medical instruments supplier reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.13. The medical instruments supplier had revenue of $28.51 million for the quarter, compared to analysts' expectations of $28.50 million. Endologix had a negative trailing twelve-month return on equity of 63.96% and a negative net margin of 44.65%.

When did Endologix's stock split?

Shares of Endologix reverse split on the morning of Wednesday, March 6th 2019.The 1-10 reverse split was announced on Tuesday, March 5th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 5th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Endologix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Endologix investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH) and Gran Tierra Energy (GTE).

Company Calendar

• Last Earnings: 5/11/2020
• Today: 7/08/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & Medical Instruments
• Sub-Industry: Health Care Supplies
• Current Symbol: NASDAQ:ELGX
• CIK: 1013606
• Web: www.endologix.com
• Phone: 949-595-7200
• Fax: N/A
• Employees: 528
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$64.76 million
• Net Margins: -44.65%
• Pretax Margin: N/A
• Return on Equity: -63.96%
• Return on Assets: -13.26%

Debt

• Debt-to-Equity Ratio: 0.29
• Current Ratio: 0.39
• Quick Ratio: 0.28

Sales & Book Value

• Annual Sales: $143.37 million
• Price / Sales: 0.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.56 per share
• Price / Book: 0.02

Miscellaneous

• Outstanding Shares: 19,172,000
• Free Float: N/A
• Market Cap: $1.41 million
• Optionable: Optionable
• Beta: 0.73